Segment, Geographic and Other Revenue Information (Tables)

3 Months Ended

Mar. 29, 2020

Reconciliation of Revenue from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Three Months Ended
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	March 29, 2020		March 31, 2019		March 29, 2020			March 31, 2019
Reportable Segments:
Biopharma	$	10,007	$	9,045	$	6,729		$	5,883
Upjohn	2,022		3,214		1,191			2,279
Total reportable segments	12,028		12,259		7,920			8,162
Other business activities	—		858		(1,489		)	(1,113		)
Reconciling Items:
Corporate and other unallocated	—		—		(1,110		)	(1,278		)
Purchase accounting adjustments	—		—		(812		)	(1,038		)
Acquisition-related costs	—		—		(13		)	(28		)
Certain significant items^(b)	—		—		(612		)	(382		)
	$	12,028	$	13,118	$	3,885		$	4,323


^(a)	Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.


^(b)	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Three Months Ended
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	March 29, 2020		March 31, 2019		March 29, 2020			March 31, 2019
Reportable Segments:
Biopharma	$	10,007	$	9,045	$	6,729		$	5,883
Upjohn	2,022		3,214		1,191			2,279
Total reportable segments	12,028		12,259		7,920			8,162
Other business activities	—		858		(1,489		)	(1,113		)
Reconciling Items:
Corporate and other unallocated	—		—		(1,110		)	(1,278		)
Purchase accounting adjustments	—		—		(812		)	(1,038		)
Acquisition-related costs	—		—		(13		)	(28		)
Certain significant items^(b)	—		—		(612		)	(382		)
	$	12,028	$	13,118	$	3,885		$	4,323


^(a)	Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.


^(b)	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Schedule of Revenues by Geographic Region



The following table provides revenues by geographic area:
	Three Months Ended
(MILLIONS OF DOLLARS)	March 29, 2020		March 31, 2019		% Change
United States	$	5,651	$	6,175	(8	)
Developed Europe^(a)	1,921		2,086		(8	)
Developed Rest of World^(b)	1,456		1,535		(5	)
Emerging Markets^(c)	3,001		3,322		(10	)
Revenues	$	12,028	$	13,118	(8	)


^(a)	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.5 billion in the first quarter of 2020 and $1.7 billion in the first quarter of 2019.


^(b)	Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.

^(c)

Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Schedule of Significant Product Revenues

The following table provides detailed revenue information for several of our major products:



(MILLIONS OF DOLLARS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 29, 2020		March 31, 2019
TOTAL REVENUES		$	12,028	$	13,118
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)		$	10,007	$	9,045
Internal Medicine^(a)		$	2,332	$	2,137
Eliquis alliance revenues and direct sales	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,300		1,011
Chantix/Champix	An aid to smoking cessation treatment in adults 18 years of age or older	270		273
Premarin family	Symptoms of menopause	152		168
BMP2	Development of bone and cartilage	69		67
Toviaz	Overactive bladder	60		60
All other Internal Medicine	Various	480		559
Oncology		$	2,435	$	1,961
Ibrance	Metastatic breast cancer	1,248		1,133
Xtandi alliance revenues	Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer	209		168
Sutent	Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor	205		232
Inlyta	Advanced RCC	169		73
Xalkori	ALK-positive and ROS1-positive advanced NSCLC	149		123
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	100		80
Retacrit^(b)	Anemia	89		31
Braftovi	In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux^® (cetuximab), for the treatment of BRAF^V600E-mutant metastatic colorectal cancer after prior therapy	37		—
Mektovi	In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation	37		—
All other Oncology	Various	192		122
Hospital^{(a), (c)}		$	2,012	$	1,827
Sulperazon	Bacterial infections	187		177
Zithromax	Bacterial infections	138		104
Medrol	Anti-inflammatory glucocorticoid	129		120
Vfend	Fungal infections	74		85
Panzyga	Primary humoral immunodeficiency	74		17
Zyvox	Bacterial infections	70		64
Fragmin	Treatment/prevention of venous thromboembolism	59		60
Pfizer CentreOne^(d)	Various	152		176
All other Anti-infectives	Various	444		405
All other Hospital^(c)	Various	684		620
Vaccines		$	1,611	$	1,612
Prevnar 13/Prevenar 13	Pneumococcal disease	1,450		1,486
Nimenrix	Meningococcal disease	75		50
All other Vaccines	Various	86		77
Inflammation & Immunology (I&I)		$	978	$	1,037
Xeljanz	RA, PsA, UC	451		423
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	347		451
Inflectra/Remsima^(b)	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	158		138
All other I&I	Various	22		25
Rare Disease		$	639	$	470
Vyndaqel/Vyndamax	ATTR-cardiomyopathy and polyneuropathy	231		41
BeneFIX	Hemophilia B	121		125
Genotropin	Replacement of human growth hormone	103		107
Refacto AF/Xyntha	Hemophilia A	89		106
Somavert	Acromegaly	64		59
All other Rare Disease	Various	31		31



(MILLIONS OF DOLLARS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 29, 2020		March 31, 2019
UPJOHN^(a)		$	2,022	$	3,214
Lipitor	Reduction of LDL cholesterol	405		622
Lyrica	Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury	357		1,186
Norvasc	Hypertension	197		300
Celebrex	Arthritis pain and inflammation, acute pain	156		174
Viagra	Erectile dysfunction	127		145
Zoloft	Depression and certain anxiety disorders	78		69
Effexor	Depression and certain anxiety disorders	77		77
EpiPen^(a)	Epinephrine injection used in treatment of life-threatening allergic reactions	72		56
Xalatan/Xalacom	Glaucoma and ocular hypertension	61		62
All other Upjohn	Various	492		523
CONSUMER HEALTHCARE BUSINESS^(e)		$	—	$	858
Total Alliance revenues	Various	$	1,382	$	1,090
Total Biosimilars^(b)	Various	$	288	$	179
Total Sterile Injectable Pharmaceuticals^(f)		$	1,407	$	1,237

^(a)

Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.


^(b)	Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.

^(c)

Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne^(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.


^(d)	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.


^(e)	On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.

^(f)

Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.